CytomX Therapeutics (CTMX) Lowered to Hold at BidaskClub

BidaskClub cut shares of CytomX Therapeutics (NASDAQ:CTMX) from a buy rating to a hold rating in a research note published on Wednesday.

A number of other research analysts have also recently issued reports on CTMX. Citigroup started coverage on shares of CytomX Therapeutics in a research note on Friday, January 5th. They issued a buy rating and a $40.00 price objective on the stock. Zacks Investment Research cut shares of CytomX Therapeutics from a hold rating to a sell rating in a research note on Wednesday, January 24th. Cantor Fitzgerald set a $40.00 price objective on shares of CytomX Therapeutics and gave the company a buy rating in a research note on Thursday, March 8th. Bank of America lifted their price objective on shares of CytomX Therapeutics from $34.00 to $40.00 and gave the company a buy rating in a research note on Thursday, March 8th. Finally, Jefferies Group lifted their price objective on shares of CytomX Therapeutics to $40.00 and gave the company a buy rating in a research note on Thursday, March 8th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $37.86.

Shares of NASDAQ:CTMX opened at $27.01 on Wednesday. The company has a market capitalization of $1,018.18, a P/E ratio of -23.28 and a beta of 0.91. CytomX Therapeutics has a 1 year low of $13.00 and a 1 year high of $35.00.



CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Wednesday, March 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.45. The business had revenue of $27.07 million for the quarter, compared to analysts’ expectations of $10.70 million. CytomX Therapeutics had a negative net margin of 60.17% and a negative return on equity of 71.42%. equities analysts anticipate that CytomX Therapeutics will post -1.44 EPS for the current fiscal year.

In other CytomX Therapeutics news, insider Rachel Humphrey sold 23,840 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $30.00, for a total value of $715,200.00. Following the sale, the insider now owns 54,074 shares in the company, valued at $1,622,220. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Debanjan Ray sold 2,548 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $26.69, for a total transaction of $68,006.12. Following the completion of the sale, the chief financial officer now owns 4,741 shares in the company, valued at approximately $126,537.29. The disclosure for this sale can be found here. Insiders sold 103,548 shares of company stock worth $3,101,686 in the last 90 days. Company insiders own 4.70% of the company’s stock.

Several large investors have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of CytomX Therapeutics by 28.5% during the fourth quarter. BlackRock Inc. now owns 2,646,599 shares of the biotechnology company’s stock worth $55,870,000 after purchasing an additional 586,698 shares during the period. Perceptive Advisors LLC lifted its holdings in shares of CytomX Therapeutics by 79.1% during the fourth quarter. Perceptive Advisors LLC now owns 2,490,381 shares of the biotechnology company’s stock worth $52,571,000 after purchasing an additional 1,100,000 shares during the period. Millennium Management LLC lifted its holdings in shares of CytomX Therapeutics by 34.0% during the fourth quarter. Millennium Management LLC now owns 837,415 shares of the biotechnology company’s stock worth $17,678,000 after purchasing an additional 212,423 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of CytomX Therapeutics by 32.9% during the fourth quarter. Renaissance Technologies LLC now owns 715,100 shares of the biotechnology company’s stock worth $15,096,000 after purchasing an additional 177,200 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of CytomX Therapeutics by 40.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 457,619 shares of the biotechnology company’s stock worth $9,660,000 after purchasing an additional 132,454 shares during the period. Institutional investors own 78.07% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://stocknewstimes.com/2018/04/22/cytomx-therapeutics-ctmx-lowered-to-hold-at-bidaskclub.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply